Pharmacotherapeutics for dyslipidemia management

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Dyslipidemia significantly increases cardiovascular (CV) risk.
• Effective lipid management is essential for preventing CV complications.
• Current clinical guidelines recommend specific interventions for lipid correction.

Purpose of the Study:

• To provide an overview of dyslipidemia treatment options.
• To focus on pharmacologic interventions for patients with dyslipidemia and CV disease.
• To highlight major drug classes used in lipid management.

Main Methods:

• Review of current clinical practice guidelines.
• Summary of evidence for various lipid-lowering drug classes.
• Focus on HMG-CoA reductase inhibitors, ezetimibe, bile acid sequestrants, fibrates, icosapent ethyl, and PCSK9 inhibitors.

Main Results:

• Multiple drug classes are available for managing dyslipidemia.
• Statins, ezetimibe, PCSK9 inhibitors, and others offer effective lipid-lowering strategies.
• Treatment selection depends on patient-specific factors and CV risk.

Conclusions:

• Comprehensive management of dyslipidemia is vital for cardiovascular health.
• Pharmacologic therapies play a key role in achieving lipid goals.
• Adherence to guidelines ensures optimal treatment for patients with dyslipidemia and CV disease.